Skip to main content

Advertisement

SpringerLink
Log in

Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Background and Objective

Immune escape by tumors can occur by multiple mechanisms, each a significant barrier to immunotherapy. We previously demonstrated that upregulation of the immunosuppressive molecule CD200 on chronic lymphocytic leukemia cells inhibits Th1 cytokine production required for an effective cytotoxic T cell response. CD200 expression on human tumor cells in animal models prevents human lymphocytes from rejecting the tumor; treatment with an antagonistic anti-CD200 antibody restored lymphocyte-mediated tumor growth inhibition. The current study evaluated CD200 expression on solid cancers, and its effect on immune response in vitro.

Methods and Results

CD200 protein was expressed on the surface of 5/8 ovarian cancer, 2/4 melanoma, 2/2 neuroblastoma and 2/3 renal carcinoma cell lines tested, but CD200 was absent on prostate, lung, breast, astrocytoma, or glioblastoma cell lines. Evaluation of patient samples by immunohistochemistry showed strong, membrane-associated CD200 staining on malignant cells of melanoma (4/4), ovarian cancer (3/3) and clear cell renal cell carcinoma (ccRCC) (2/3), but also on normal ovary and kidney. CD200 expression on melanoma metastases was determined by RT-QPCR, and was found to be significantly higher in jejunum metastases (2/2) and lung metastases (2/6) than in normal samples. Addition of CD200-expressing, but not CD200-negative solid tumor cell lines to mixed lymphocyte reactions downregulated the production of Th1 cytokines. Inclusion of antagonistic anti-CD200 antibody restored Th1 cytokine responses.

Conclusion

These data suggest that melanoma, ccRCC and ovarian tumor cells can express CD200, thereby potentially suppressing anti-tumor immune responses. CD200 blockade with an antagonistic antibody may permit an effective anti-tumor immune response in these solid tumor types.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R et al (2003) Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23(3A):1969–1996

    PubMed  CAS  Google Scholar 

  2. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI et al (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103(4):1041–1046

    Article  PubMed  CAS  Google Scholar 

  3. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D et al (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178(9):5595–5605

    PubMed  CAS  Google Scholar 

  4. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108(13):4194–4197

    Article  PubMed  CAS  Google Scholar 

  5. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3):566–568

    Article  PubMed  CAS  Google Scholar 

  6. Barclay AN, Clark MJ, McCaughan GW (1986) Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 51:149–157

    PubMed  CAS  Google Scholar 

  7. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN (2001) The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102(2):173–179

    Article  PubMed  CAS  Google Scholar 

  8. Barclay AN, Wright GJ, Brooke G, Brown MH (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 23(6):285–290

    Article  PubMed  CAS  Google Scholar 

  9. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM et al (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290(5497):1768–1771

    Article  PubMed  CAS  Google Scholar 

  10. Gorczynski RM, Cattral MS, Chen Z, Hu J, Lei J, Min WP et al (1999) An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163(3):1654–1660

    PubMed  CAS  Google Scholar 

  11. Clark DA, Yu G, Levy GA, Gorczynski RM (2001) Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. Semin Immunol 13(4):255–263

    Article  PubMed  CAS  Google Scholar 

  12. Gorczynski RM, Chen Z, Clark DA, Kai Y, Lee L, Nachman J et al (2004) Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface. Am J Reprod Immunol 52(2):147–163

    Article  PubMed  Google Scholar 

  13. Freedman LR, Cerottini JC, Brunner KT (1972) In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 109(6):1371–1378

    PubMed  CAS  Google Scholar 

  14. Bevan MJ, Cohn M (1975) Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol 114(2 Pt 1):559–565

    PubMed  CAS  Google Scholar 

  15. Chattopadhyay S, Chakraborty NG (2005) Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum Immunol 66(8):884–891

    Article  PubMed  CAS  Google Scholar 

  16. Tendler CL, Burton JD, Jaffe J, Danielpour D, Charley M, McCoy JP et al (1994) Abnormal cytokine expression in Sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 54(16):4430–4435

    PubMed  CAS  Google Scholar 

  17. Takeuchi T, Ueki T, Sasaki Y, Kajiwara T, Li B, Moriyama N et al (1997) Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 43(6):375–381

    Article  PubMed  CAS  Google Scholar 

  18. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM (2000) Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44(4):271–274

    Article  PubMed  CAS  Google Scholar 

  19. Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J et al (2002) Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49(3):159–166

    PubMed  CAS  Google Scholar 

  20. Tabata T, Hazama S, Yoshino S, Oka M (1999) Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg 177(3):203–208

    Article  PubMed  CAS  Google Scholar 

  21. Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L (2004) Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 77(8):1138–1144

    Article  PubMed  CAS  Google Scholar 

  22. Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Gizzi S, Fioretti MC et al (2004) Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173(6):3748–3754

    PubMed  CAS  Google Scholar 

  23. Gorczynski RM, Lee L, Boudakov I (2005) Augmented induction of CD4 + CD25 +  Treg using monoclonal antibodies to CD200R. Transplantation 79(4):488–491

    PubMed  CAS  Google Scholar 

  24. Mueller JP, Giannoni MA, Hartman SL, Elliott EA, Squinto SP, Matis LA et al (1997) Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 34(6):441–452

    Article  PubMed  CAS  Google Scholar 

  25. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O’Brian CA (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 151(1):225–234

    Article  PubMed  Google Scholar 

  26. Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z (2005) Recovery of CD8 + T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 65(15):7000–7006

    Article  PubMed  CAS  Google Scholar 

  27. Bondurant KL, Crew MD, Santin AD, O’Brien TJ, Cannon MJ (2005) Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Clin Cancer Res 11(9):3446–3454

    Article  PubMed  CAS  Google Scholar 

  28. Romero P, Cerottini JC, Speiser DE (2006) The human T cell response to melanoma antigens. Adv Immunol 92:187–224

    PubMed  Google Scholar 

  29. Faries MB, Morton DL (2005) Therapeutic vaccines for melanoma: current status. BioDrugs 19(4):247–260

    Article  PubMed  CAS  Google Scholar 

  30. Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother (1997) 29(3):233–240

    Article  CAS  Google Scholar 

  31. Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS et al (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171(9):4650–4654

    PubMed  CAS  Google Scholar 

  32. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4):871–881

    Article  PubMed  CAS  Google Scholar 

  33. Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL et al (2006) B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66(3):1570–1575

    Article  PubMed  CAS  Google Scholar 

  34. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S et al (2006) B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100(1):44–52

    Article  PubMed  CAS  Google Scholar 

  35. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800

    PubMed  CAS  Google Scholar 

  36. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B et al (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119(2):317–327

    Article  PubMed  CAS  Google Scholar 

  37. Ichikawa M, Chen L (2005) Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Front Biosci 10:2856–2860

    Article  PubMed  CAS  Google Scholar 

  38. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562–567

    Article  PubMed  CAS  Google Scholar 

  39. Kacinski BM, Stanley ER, Carter D, Chambers JT, Chambers SK, Kohorn EI et al (1989) Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys 17(1):159–164

    PubMed  CAS  Google Scholar 

  40. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr, Brown EL (1989) Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83(3):921–926

    Article  PubMed  CAS  Google Scholar 

  41. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB et al (1993) Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53(8):1939–1944

    PubMed  CAS  Google Scholar 

  42. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR (2005) The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 92(7):1182–1187

    Article  PubMed  CAS  Google Scholar 

  43. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12(12):1005–1016

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alexion Antibody Technologies, Inc., 3985 Sorrento Valley Blvd, Ste A, San Diego, CA, 92121, USA

    A. Siva, H. Xin, F. Qin, D. Oltean, K. S. Bowdish & A. Kretz-Rommel

Authors
  1. A. Siva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Oltean
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. S. Bowdish
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Kretz-Rommel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Kretz-Rommel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siva, A., Xin, H., Qin, F. et al. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57, 987–996 (2008). https://doi.org/10.1007/s00262-007-0429-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-007-0429-6

Keywords

Search

Navigation